Last reviewed · How we verify
MSC-1
At a glance
| Generic name | MSC-1 |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours (PHASE2)
- Mesenchymal Stem Cell Transfusion for the Treatment of Refractory Lupus Nephritis (EARLY_PHASE1)
- Human Umbilical Cord Mesenchymal Stem Cell Transplantation for The Treatment of Acute-on-Chronic Liver Failure (PHASE1, PHASE2)
- Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors (PHASE1)
- Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise (PHASE2)
- Effects of Repeated Mesenchymal Stem Cells (MSC) in Patients With Progressive Multiple Sclerosis (PHASE1, PHASE2)
- BM-MNCs and UC-MSCs Infusion for Type 2 Diabetes Mellitus Patients (PHASE1, PHASE2)
- Mesenchymal Stem Cells In Cisplatin-Induced Acute Renal Failure In Patients With Solid Organ Cancers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MSC-1 CI brief — competitive landscape report
- MSC-1 updates RSS · CI watch RSS
- AstraZeneca portfolio CI